LON:SBTX SkinBioTherapeutics Share Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding SkinBioTherapeutics Plc Please log in to your account or sign up in order to add this asset to your watchlist. GBX 19.26 -0.25 (-1.26%) (As of 06/30/2022 08:01 AM ET) Add Compare Share Today's Range 19.26▼ 19.2650-Day Range 19▼ 3052-Week Range 17▼ 78.25Volume47,408 shsAverage Volume450,619 shsMarket Capitalization£30.19 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileChartCompetitorsEarningsInsider TradesHeadlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive SBTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SkinBioTherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address SBTX Stock Forecast (MarketRank)Overall MarketRank™0.80 out of 5 starsAnalyst Opinion: 0.0Community Rank: 4.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 - 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for SkinBioTherapeutics. Previous Next 4.0 Community Rank Outperform VotesSkinBioTherapeutics has received 47 “outperform” votes. (Add your “outperform” vote.)Underperform VotesSkinBioTherapeutics has received 31 “underperform” votes. (Add your “underperform” vote.)Community SentimentSkinBioTherapeutics has received 60.26% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about SkinBioTherapeutics and other stocks. Vote “Outperform” if you believe SBTX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe SBTX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldSkinBioTherapeutics does not currently pay a dividend.Dividend GrowthSkinBioTherapeutics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, SkinBioTherapeutics insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of SkinBioTherapeutics is -16.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of SkinBioTherapeutics is -16.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSkinBioTherapeutics has a P/B Ratio of 7.13. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About SkinBioTherapeutics (LON:SBTX)SkinBioTherapeutics plc, a life science company, engages in the research and development of technology that harnesses the human microbiome to improve health. The company develops SkinBiotix technology that can enhance the barrier effect of skin models, protect skin from infections, and repair wounds; and AxisBiotix that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis. It serves cosmetic skincare, food supplements, medical skin care, infection control, and pharmaceutical skincare markets. The company has a collaboration agreement with Croda Plc; the University of Manchester to develop immune-supporting microbiome formulations; and Winclove Probiotics B.V. for the development of a probiotic blend of good bacterial strains based on the modifying properties of specific bacterial species in known psoriasis pathways. The company was formerly known as Skinbiotix Ltd and changed its name to SkinBioTherapeutics plc in December 2016. SkinBioTherapeutics plc was incorporated in 2015 and is based in Newcastle upon Tyne, the United Kingdom.Read More SBTX Stock News HeadlinesJune 15, 2022 | proactiveinvestors.comSkinBioTherapeutics puzzled by share price, says feedback positive for psoriasis treatmentJune 13, 2022 | marketwatch.comSkinBioTherapeutics Knows No Reason For Share Price FallMay 18, 2022 | finance.yahoo.comWe're Keeping An Eye On SkinBioTherapeutics' (LON:SBTX) Cash Burn RateMarch 29, 2022 | lse.co.ukSkinBioTherapeutics proposes Manprit Singh Randhawa as new CFOMarch 29, 2022 | marketwatch.comSkinBioTherapeutics Shares Drop 30% After Widened 1H Pretax LossFebruary 17, 2022 | finance.yahoo.comWhat Kind Of Shareholders Hold The Majority In SkinBioTherapeutics Plc's (LON:SBTX) Shares?January 19, 2022 | marketwatch.comSkinBioTherapeutics CFO to Step DownJanuary 18, 2022 | proactiveinvestors.comSkinBioTherapeutics seeks full-time finance chief and NED to guide social media strategyDecember 24, 2021 | markets.businessinsider.comSkinBioTherapeutics : Result of AGMDecember 4, 2021 | markets.businessinsider.comSkinBioTherapeutics : Notice of ResultsNovember 30, 2021 | marketwatch.comSkinBioTherapeutics Workflow Disrupted by Pandemic; Shares FallNovember 22, 2021 | markets.businessinsider.comSkinBioTherapeutics : Placing of SharesNovember 15, 2021 | marketwatch.comSkinBioTherapeutics Launches Discounted Share PlacingSee More Headlines Industry, Sector and Symbol Stock ExchangeLON Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolLON:SBTX CUSIPN/A CIKN/A Webwww.skinbiotherapeutics.com Phone+44-161-4682760FaxN/AEmployees7Year FoundedN/ACompany Calendar Last Earnings3/03/2020Today6/29/2022Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio3.07 Current Ratio11.19 Quick Ratio10.01 Sales & Book Value Annual Sales£21.95 thousand Price / Sales1,375.37 Cash FlowGBX 1.86 per share Price / Cash Flow10.38 Book ValueGBX 2.70 per share Price / Book7.13Miscellaneous Outstanding Shares156,780,000Free FloatN/AMarket Cap£30.19 million OptionableNot Optionable BetaN/A SkinBioTherapeutics Frequently Asked Questions How has SkinBioTherapeutics' stock price performed in 2022? SkinBioTherapeutics' stock was trading at GBX 42 on January 1st, 2022. Since then, SBTX shares have decreased by 54.2% and is now trading at GBX 19.26. View the best growth stocks for 2022 here. How were SkinBioTherapeutics' earnings last quarter? SkinBioTherapeutics Plc (LON:SBTX) released its quarterly earnings data on Tuesday, March, 3rd. The company reported ($0.64) EPS for the quarter. View SkinBioTherapeutics' earnings history. Who are SkinBioTherapeutics' key executives? SkinBioTherapeutics' management team includes the following people: Mr. Stuart John Ashman, CEO & Exec. Director (Age 55, Pay $328.82k)Mr. Douglas John Quinn, Company Sec.Manprit Singh Randhawa, Chief Financial Officer (Age 39)Dr. Catherine O'Neill, Chief Scientific Officer & Member of Scientific Advisory Board Who are some of SkinBioTherapeutics' key competitors? Some companies that are related to SkinBioTherapeutics include Faron Pharmaceuticals Oy (FARN), Tiziana Life Sciences (TILS), ImmunoPrecise Antibodies (IPA), Verseon (VSN), Novacyt (NCYT), Scancell (SCLP), Scythian Biosciences (SCYB), 138267 (COM.TO) (COM), Novoheart (NVH), Aptose Biosciences (APS), Arecor Therapeutics (AREC), e-therapeutics (ETX), Mereo BioPharma Group plc (MPH.L) (MPH), Medicenna Therapeutics (MDNA) and Ondine Biomedical (OBI). View all of SBTX's competitors. What other stocks do shareholders of SkinBioTherapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other SkinBioTherapeutics investors own include Anglo Pacific Group (APF), Avacta Group (AVCT), Inspired (INSE), OptiBiotix Health (OPTI), Lb-shell (LBP), Anglo African Oil & Gas (AAOG), Big Sofa Technologies Group (BST), Concepta PLC (CPT.L) (CPT), Fresnillo (FRES) and Shield Therapeutics (STX). What is SkinBioTherapeutics' stock symbol? SkinBioTherapeutics trades on the London Stock Exchange (LON) under the ticker symbol "SBTX." How do I buy shares of SkinBioTherapeutics? Shares of SBTX and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. What is SkinBioTherapeutics' stock price today? One share of SBTX stock can currently be purchased for approximately GBX 19.26. How much money does SkinBioTherapeutics make? SkinBioTherapeutics (LON:SBTX) has a market capitalization of £30.19 million and generates £21.95 thousand in revenue each year. How many employees does SkinBioTherapeutics have? SkinBioTherapeutics employs 7 workers across the globe. How can I contact SkinBioTherapeutics? SkinBioTherapeutics' mailing address is 15 1 Silk House, Park Green, MACCLESFIELD, SK11 7QJ, United Kingdom. The official website for SkinBioTherapeutics is www.skinbiotherapeutics.com. The company can be reached via phone at +44-161-4682760. This page (LON:SBTX) was last updated on 6/30/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
